Costs and effects of various analgesic treatments for patients with rheumatoid arthritis and osteoarthritis in The Netherlands

Value in Health

Volumn 11, Issue 4, 2008, Pages 589-599

  Al, Maiwenn J ^a   Maniadakis, Nikos ^b   Grijseels, Els W M ^a   Janssen, Matthijs ^c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY GENERAL HOSPITAL OF PATRAS   (Greece)

^c RIJNSTATE HOSPITAL   (Netherlands)

Author keywords

Arthritis; Celecoxib; Cost effectiveness; NSAIDs; Selective COX 2 inhibitors

Indexed keywords

ANALGESIC AGENT; ARTHROTEC; CELECOXIB; CIMETIDINE; DICLOFENAC; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; LANSOPRAZOLE; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE;

ANEMIA; ARTICLE; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DRUG CHOICE; DRUG COST; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; GASTROINTESTINAL SYMPTOM; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; NETHERLANDS; OSTEOARTHRITIS; PRIORITY JOURNAL; PROBABILITY; RHEUMATOID ARTHRITIS; ULCER;

EID: 47849094630     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2007.00303.x     Document Type: Article

References (55)

1. Miedema HS. Reuma in Nederland: de cijfers. Leiden : TNO Preventie en Gezondheid, 1997.
2. Schouten JSAG. Artrose. In : Maas IAM, Gijsen R, Lobbezoo IE, Poos MJJC, eds. Volksgezondheid Toekomst Verkenningen 1997. De gezondheidstoestand: een actualisering. Bilthoven : Elsevier/De Tijdstroom, 1997.
3. Moens HJ, van Croonenborg JJ, Al MJ, et al. Guideline "NSAID use and the prevention of gastric damage" (in Dutch). Ned Tijdschr Geneeskd 2004 148 : 604 8.
4. Herings RM, Klungel OH. An epidemiological approach to assess the economic burden of NSAID-induced gastrointestinal events in The Netherlands. Pharmacoeconomics 2001 19 : 655 65.
5. Herings RMC, Panneman MJM, Lodder AC, et al. Farmacotherapie in Beweging. Utrecht : PHARMO Instituut, 2000.
6. Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999 282 : 1921 8.
7. Emery P, Zeidler H, Kvien TK, et al. Celecoxib versus diclofenac in longterm management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999 354 : 2106 11.
8. Burke TA, Zabinski RA, Pettitt D, et al. A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or celecoxib in the treatment of arthritis. Pharmacoeconomics 2001 19 (Suppl. 1 S33 47.
9. Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ 2002 325 : 619.
10. Cullen D, Bardhan KD, Eisner M, et al. Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. Aliment Pharmacol Ther 1998 12 : 135 40.
11. Ekström P, Carling L, Wetterhus S, et al. Prevention of gastric ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. Scand J Gastroenterol 1996 31 : 753 8.
12. Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998 338 : 727 34.
13. Levine LR, Cloud ML, Enas NH. Nizatidine prevents peptic ulceration in high-risk patients taking nonsteroidal anti-inflammatory drugs. Arch Intern Med 1993 153 : 2449 54.
14. Rugstad HE, Giercksky KE, Husby G, et al. Effect of cimetidine on gastrointestinal symptoms in patients taking nonsteroidal anti-infammatory drugs. Scand J Rheumatol 1994 23 : 177 82.
15. Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiiflammatory drugs. N Engl J Med 1996 334 : 1435 9.
16. Agrawal NM, van Kerckhove HEJM, Erhardt LJ, et al. Misoprostol coadministered with diclofenac for prevention of gastroduodenal ulcers: a one-year study. Dig Dis Sci 1995 40 : 1125 31.
17. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. Ann Intern Med 1995 123 : 241 9.
18. Raskin JB, White RH, Jackson JE, et al. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med 1995 123 : 344 50.
19. Roth SH. Misoprostol in the prevention of NSAID-induced gastric ulcer: a multicenter, double-blind, placebo-controlled trial. J Rheumatol 1990 17 (Suppl. 20 S2024.
20. Graham DY, White RH, Moreland LW, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann Intern Med 1993 119 : 257 62.
21. Elliott SL, Yeomans ND, Buchanan RRC, et al. Efficacy of 12 months' misoprostol as prophylaxis against NSAID-induced gastric ulcers. Scand J Rheumatol 1994 23 : 171 6.
22. Bocanegra TS, Weaver AL, Tindall EA, et al. Diclofenac/misoprostol compared with diclofenac in the treatment of osteoarthritis of the knee or hip: a randomized, placebo controlled trial. J Rheumatol 1998 25 : 1602 11.
23. Melo Gomes JA, Roth SH, Bruyn GAW, et al. Double-blind comparison of efficacy and gastroduodenal safety of diclofenac/misoprostol, piroxicam, and naproxen in the treatment of osteoarthritis. Ann Rheum Dis 1993 52 : 881 5.
24. Verdickt W, Moran C, Hantzschel H, et al. A double-blind comparison of the gastroduodenal safety and efficacy of diclofenac and a fixed dose combination of diclofenac and misoprostol in the treatment of rheumatoid arthritis. Scand J Rheumatol 1992 21 : 85 91.
25. Bolten W, Melo Gomes JA, Stead H, et al. The gastroduodenal safety and efficacy of the fixed combination of diclofenac and misoprostol in the treatment of osteoarthritis. Br J Rheumatol 1992 31 : 753 8.
26. Agrawal NM, Caldwell J, Kivitz AJ, et al. Comparison of the upper gastrointestinal safety of Arthrotec 75 and nabumetone in osteoarthritis patients at high risk for developing nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers. Clin Ther 1999 21 : 659 74.
27. Fries JF, Williams CA, Bloch DA. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med 1991 91 : 213 22.
28. Simon LS, Hatoum HT, Bittman RM, et al. Risk factors for serious nonsteroidal-induced gastrointestinal complications: regression analysis of the MUCOSA trial. Fam Medical 1996 28 : 204 10.
29. Singh G, Ramey D, Triadafilopoulos G, et al. GI score: a simple self-assessment instrument to quantify the risk of serious NSAID-related complications in RA and OA [abstract]. Arthritis Rheum 1996 39 (Suppl. S75.
30. National Institute for Clinical Excellence. Guidance on the Use of Cyclo-Oxygenase (COX) II Selective Inhibitors, Celecoxib, Rofecoxib, Meloxicam and Etodolac for Osteoarthitis and Theumatoid Arthritis. London : NHS, 2001.
31. Fries JF. Assessing and understanding patient risk. Scand J Rheumatol 1992 Suppl. 92 S21 4.
32. Al MJ, Michel BC, Rutten FFH. The cost effectiveness of diclofenac plus misoprostol compared with diclofenac monotherapy in patients with rheumatoid arthritis. Pharmacoeconomics 1996 10 : 141 51.
33. Ruwaard D, Kramers PGN, eds. Volksgezondheid Toekomst Verkenning 1997: De som de delen. Utrecht : De Tijdstroom, 1997.
34. Oostenbrink JB, Bouwmans CAM, Koopmanschap MA, et al. Handleiding voor kostenonderzoek: Methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg. Geactualiseerde versie 2004. Diemen : College voor Zorgverzekeringen, 2004.
35. Doubilet P, Begg CB, Weinstein MC, et al. Probabilistic sensitivity analysis using Monte Carlo simulation. Med Decis Making 1985 5 : 157 77.
36. van Hout BA, Al MJ, Gordon GS, et al. Costs, effects and c/e-ratios alongside a clinical trial. Health Econ 1994 3 : 309 19.
37. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001 10 : 779 87.
38. Karlsson G, Johannesson M. The decision rules of cost-effectiveness analysis. Pharmacoeconomics 1996 9 : 113 20.
39. Centraal begeleidingsorgaan voor de Intercollegiale Toetsing. Behandeling en preventie van coronaire hartziekte door verlaging van de plasmacholesterolconcentratie. Utrecht : Centraal begeleidingsorgaan voor de Intercollegiale Toetsing, 1998.
40. Niessen LW, Dippel DWJ, Limburg M. Berekening van kosten na beroerte en kosteneffectiviteit van "stroke units" en van secundaire preventie, zoals aanbevolen in de herziene CBO-richtlijn "Beroerte" [Calculation of costs and cost-effectiveness of stroke units and of secundary prevention in patients after a stroke, as recommended in the revised CBO guideline "Stroke"]. Ned Tijdschr Geneeskd 2000 144 : 1959 64.
41. Zabinski RA, Burke TA, Johnson J, et al. An economic model for determining the costs and consequences of using various treatment alternatives for the management of arthritis in Canada. Pharmacoeconomics 2001 19 (Suppl. 1 S49 58.
42. Chancellor JVM, Hunsche E, de Cruz E, et al. Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland. Pharmacoeconomics 2001 19 (Suppl. 1 S59 75.
43. Spiegel BM, Targownik L, Dulai GS, et al. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. Ann Intern Med 2003 138 : 795 806.
44. Maetzel A, Krahn M, Naglie G. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Arthritis Rheum 2003 49 : 283 92.
45. Yen ZS, Lai MS, Wang CT, et al. Cost-effectiveness of treatment strategies for osteoarthritis of the knee in Taiwan. J Rheumatol 2004 31 : 1797 803.
46. Haglund U, Svarvar P. The Swedish ACCES model: predicting the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis. Rheumatology (Oxford) 2000 39 (Suppl. 2 S51 6.
47. MacDonald TM, Morant SV, Robinson GC, et al. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study. BMJ 1997 315 : 1333 7.
48. EMEA. Summary of the product characteristics celebrex 2007. Available from: http://emc.medicines.org.uk/emc/assets/c/html/DisplayDoc.asp?DocumentID= 14534 [Accessed December 7, 2007].
49. Hernandez-Diaz S, Varas-Lorenzo C, Garcia Rodriguez LA. Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol 2006 98 : 266 74.
50. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. JAMA 2000 284 : 1247 55.
51. Hrachovec JB, Mora M. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib [letter]. JAMA 2001 286 : 2398.
52. Juni P, Rutjes AWS, Dieppe PA. Are selective COX 2 inhibitors superior to traditional nonsteroidal anti-inflammatory drugs? BMJ 2002 324 : 1287 8.
53. Wright JM, Perry TL, Bassett KL, et al. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib [letter]. JAMA 2001 286 : 2398 40.
54. Sturkenboom MC, Burke TA, Tangelder MJ, et al. Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2003 18 : 1137 47.
55. Sturkenboom MC, Burke TA, Dieleman JP, et al. Underutilization of preventive strategies in patients receiving NSAIDs. Rheumatology 2003 42 (Suppl. 3 S23 31.